HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a research note published on Thursday, Benzinga reports. They currently have a $8.00 target price on the stock.
Other analysts also recently issued research reports about the stock. Chardan Capital reaffirmed a buy rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Wednesday, March 27th. Oppenheimer reaffirmed an outperform rating and issued a $9.00 price target on shares of Gain Therapeutics in a report on Tuesday, April 23rd.
Read Our Latest Report on GANX
Gain Therapeutics Stock Up 1.5 %
Gain Therapeutics (NASDAQ:GANX – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. On average, research analysts expect that Gain Therapeutics will post -1.03 earnings per share for the current fiscal year.
About Gain Therapeutics
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Read More
- Five stocks we like better than Gain Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Top 3 Defense Stocks That Should Be on Your Radar
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.